mds
No description yet: the sentence for this tag has not been written. 4 records carry it: 4 people. Also written “MDS”; the spellings share this page.
4 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Amer M. Zeidan Haematologist, Yale Cancer Center · Yale Cancer Center / Smilow Cancer Hospital Yale haematologist who led VERONA, the trial that asked whether adding venetoclax to azacitidine helps people with higher-risk myelodysplastic syndromes, and found it did not lengthen survival. | Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms | none | trialist | ||
Marc H.G.P. Raaijmakers Vice Chair · HOVON Erasmus MC haematologist and HOVON Vice Chair known for research on the bone marrow microenvironment in MDS. | Myelodysplastic syndromes / neoplasms, Acute myeloid leukaemia | none | leadership, clinician-scientist, haematology | ||
Pierre Fenaux Professor of Hematology, Hôpital Saint-Louis, Université Paris Cité · Cancer Institute AP-HP Nord, Université Paris Cité Led AZA-001, which showed azacitidine extends survival in high-risk MDS and made hypomethylating agents standard. | Myelodysplastic syndromes / neoplasms, Acute myeloid leukaemia | none | epigenetics, france | ||
Uwe Platzbecker Director, Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital Leipzig · Leipzig University Hospital / University Cancer Center Leipzig (UCCL) Led MEDALIST and COMMANDS, which made luspatercept a first-line treatment for anaemia in lower-risk MDS. | Myelodysplastic syndromes / neoplasms, Acute myeloid leukaemia | none | anaemia, trialist |